Story · Medicine & Biotech

ACAAI: Considerable delay seen from Rx to approval for children's biologics

1 outlet · first reported by Medical Xpress on

There is a considerable delay from prescription of biologic therapy to final approval for pediatric patients, and almost 40% of prescriptions requiring a prior authorization (PA) are denied, according to a study presented at the annual meeting of the American College of Allergy, Asthma and… (Medical Xpress)

Coverage, in order

  1. ACAAI: Considerable delay seen from Rx to approval for children's biologics

    There is a considerable delay from prescription of biologic therapy to final approval for pediatric patients, and almost 40% of prescriptions requiring a prior authorization (PA) are denied, according to a study presented at the annual meeting of the American College of Allergy, Asthma and…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.